Sign In
Buy SGEN
$228.74
+0 (+0%)
At Close: Mar 12, 2024
Trading The Top 10 Stocks From 40 Large Hedge Funds: Trading Update 9/4/2022
04:24am, Monday, 05'th Sep 2022 Seeking Alpha
A strategy selecting 10 of the 50 stocks, equally weighted, would have increased total return to 178.0%, an active return of 61.6% vs. SPY.
Biotech Hasn't Been This Blazing Hot Since Early 2021 — Here Are The Top 5
03:26pm, Wednesday, 31'st Aug 2022
The top five biotech stocks today have several commonalities: strong ratings. Some also show promising charts and are Tech Leaders.
Company News for Aug 29, 2022
01:37pm, Monday, 29'th Aug 2022 Zacks Investment Research
Companies in The News Are: AFRM,FTCH,SGEN,MRK,DELL
Apple, Amazon, HP And Other Big Losers From Friday
09:12am, Monday, 29'th Aug 2022 Benzinga
U.S. stocks closed sharply lower with the Dow Jones tumbling more than 1,000 points on Friday. Here is the list of some big stocks moving lower in the previous session.
Domo, Inc. (NASDAQ: DOMO) shar
Why Everbridge Jumped Over 17%; Here Are 90 Biggest Movers From Friday
06:55am, Monday, 29'th Aug 2022 Benzinga
Gainers
Micro Focus International plc (NYSE: MFGP) shares surged 92% to close at $6.01 on Friday after the company reached an agreement with OpenText to be acquired for $6 billion.
Minerva Neuroscien
Why Farfetch Is Trading Higher By 32%, Here Are 46 Stocks Moving In Friday's Mid-Day Session
04:52pm, Friday, 26'th Aug 2022 Benzinga
Gainers
Micro Focus International plc (NYSE: MFGP) shares jumped 95.4% to $6.11 after the company reached an agreement with OpenText to be acquired for $6 billion.
The OLB Group, Inc. (NASDAQ: OLB) g
Dell Technologies, Open Text And Some Other Big Stocks Moving Lower In Today's Pre-Market Session
11:49am, Friday, 26'th Aug 2022 Benzinga
Affirm Holdings, Inc. (NASDAQ: AFRM) shares fell 12.7% to $27.27 in pre-market trading after the company reported worse-than-expected Q4 EPS results and issued Q1 FY23 sales guidance below estimates.
Why Micro Focus International Is Trading Higher By Around 94%; Here Are 28 Stocks Moving Premarket
10:53am, Friday, 26'th Aug 2022 Benzinga
Gainers
Micro Focus International plc (NYSE: MFGP) shares rose 93.6% to $6.06 in pre-market trading after the company reached an agreement with Open Text Corporation (NASDAQ: OTEX) to be acquired fo
Merck Looks Attractive, With or Without Seagen
09:03am, Wednesday, 24'th Aug 2022
While investors are eagerly awaiting news on a Seagen tie-up, Merck offers upside even if the deal doesn't materialize.
3 Biopharmas on Buyout Watch
12:00pm, Monday, 22'nd Aug 2022 The Motley Fool
These three biotech companies could be headed for a buyout soon.
Merck (MRK) Enters Into Circular RNA Collaboration With Orna
12:47pm, Wednesday, 17'th Aug 2022 Zacks Investment Research
Merck (MRK) is set to make an upfront payment of $150 million to Orna for rights to the latter's circular RNA technology to make vaccines and therapeutics for infectious disease and oncology.
Roche's (RHHBY) sBLA For Polivy Combo Accepted by FDA
04:25pm, Tuesday, 16'th Aug 2022 Zacks Investment Research
Roche's (RHHBY) sBLA seeking approval for the use of Polivy in combination with R-CHP for previously untreated diffuse large B-cell lymphoma in adults has been accepted in the United States.
Seagen For Sale? This Acquisition Target Is 'Too Intriguing To Ignore,' RBC Says
03:03pm, Tuesday, 16'th Aug 2022 Benzinga
The recent pressure on Seagen Inc.’s (NASDAQ: SGEN) stock may offer a nearer-term opportunity, but the biotech's position as an attractive strategic target is “too intriguing to ignore.”
That's
Does Merck Finally Have The Fodder It Needs To Buy Seagen?
05:09pm, Friday, 12'th Aug 2022
Seagen lost a royalty battle Friday, but SGEN stock jumped on the potential the rumored Merck acquisition could be looming. The post Does Merck Finally Have The Fodder It Needs To Buy Seagen?
Seagen's (SGEN) Cancer Drugs Aid Growth, Stiff Rivalry a Woe
02:18pm, Thursday, 11'th Aug 2022
Seagen (SGEN) focuses on improving sales of its marketed drugs approved for different types of cancer indications. Stiff competition in the market remains a woe.
